The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2023 | Pitfalls in the diagnosis of lymphoid malignancies: interpreting PET scans
Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, briefly discusses pitfalls in the diagnosis of lymphoid malignancies, emphasizing the need to standardize approaches when conducting and interpreting the results of PET scans. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Roche, Takeda, Pfizer, Servier, Kite Gilead, MSD, Novartis, Beigene, Astra Zeneca, Syneos, Autolus, Kyowa Kirin, Abbvie, Incyte, BMS/Celgene, Janssen
